FULCRUM THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
FULCRUM THERAPEUTICS, INC. (FULC) reported Capital Expenditures Incurred but Not yet Paid of $159.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-10-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-10-29
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $159.00K, a 1.24% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $161.00K.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $19.00K.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $26.00K, a 29.73% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2021 was $37.00K, a 85.88% decline from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2020 was $262.00K, a 670.59% increase from fiscal 2019.
- FULCRUM THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2019 was $34.00K, a 80.46% decline from fiscal 2018.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2025-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $159.00K 10-Q · filed 2025-10-29 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-07-29 | |||
| 2024-09-30 | $161.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $180.00K derived: sum of 2 quarters · filed 2025-10-29 | $180.00K 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $19.00K 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-13 | |||
| 2023-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$79.00K derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $6.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $47.00K 10-Q · filed 2024-07-31 | $53.00K derived: sum of 3 quarters · filed 2024-07-31 | -$78.00K derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $79.00K 10-Q · filed 2024-05-13 | $85.00K derived: sum of 2 quarters · filed 2024-05-13 | -$46.00K derived: sum of 3 quarters · filed 2024-05-13 | -$742.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$125.00K derived: sum of 2 quarters · filed 2024-02-27 | -$821.00K derived: sum of 3 quarters · filed 2024-02-27 | $26.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$827.00K derived: sum of 2 quarters · filed 2023-11-07 | $20.00K 10-Q · filed 2023-11-07 | -$257.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$696.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $151.00K 10-Q · filed 2023-08-03 | -$126.00K derived: sum of 3 quarters · filed 2023-08-03 | $129.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $847.00K 10-Q · filed 2023-05-15 | $570.00K derived: sum of 2 quarters · filed 2023-06-26 | $825.00K derived: sum of 3 quarters · filed 2023-06-26 | $844.00K derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | -$277.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | -$22.00K derived: sum of 2 quarters · filed 2023-06-26 | -$3.00K derived: sum of 3 quarters · filed 2023-06-26 | $37.00K 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $255.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $274.00K derived: sum of 2 quarters · filed 2022-11-08 | $314.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $59.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $40.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $262.00K 10-K/A · filed 2023-06-26 | |||
| 2020-06-30 | -$109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $54.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $163.00K 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $34.00K 10-K/A · filed 2023-06-23 | |||
| 2019-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $120.00K 10-Q · filed 2020-08-11 | -$2.68M derived: sum of 3 quarters · filed 2020-08-11 | -$3.33M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $47.00K 10-Q · filed 2020-05-13 | -$2.75M derived: sum of 2 quarters · filed 2020-05-13 | -$3.40M derived: sum of 3 quarters · filed 2020-05-13 | |
| 2018-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$3.45M derived: sum of 2 quarters · filed 2020-03-05 | $174.00K 10-K · filed 2020-03-05 | |
| 2018-09-30 | -$650.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $2.98M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $3.63M 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |